Skip to main content

Table 3 Medication use in subgroups with respect to both the presence of peripheral artery disease and the presence of the metabolic syndrome

From: Insulin resistance is significantly associated with the metabolic syndrome, but not with sonographically proven peripheral arterial disease

 

PAD+/MetS+ (n = 57)

PAD+/MetS- (n = 157)

PAD-/MetS+ (n = 55)

PAD-/MetS- (n = 142)

p-value

Aspirin (%)

67.9

67.8

58.2

52.8

0.006

Clopidogrel (%)

26.8

31.1

3.6

4.9

<0.001

Metformin (%) *

30.3

5.1

9.1

5.6

0.007

Sulfonyrea (%) *

24.2

3.4

3.6

5.6

0.050

Glitazone (%) *

6.1

0.9

0.0

0.0

0.011

Insulin (%) *

15.2

10.3

3.6

5.6

0.040

Statins (%)

75.0

69.2

21.8

28.2

0.003

Angiotensin Converting Enzyme Inhibitors (%)

49.1

40.1

24.5

23.9

<0.001

Calcium Antagonists (%)

36.8

29.3

10.9

8.5

<0.001

Beta Adrenoreceptor Blocking Agents (%)

31.6

40.1

61.8

38.0

0.459

Angiotensin II Receptor Blocking Agents (%)

12.3

10.8

9.1

4.9

0.042

  1. PAD denotes peripheral artery disease.
  2. * Percentage of subjects with type 2 diabetes (n = 87 and 45 in the PAD and in the control group, respectively).